Maple Rock Capital Partners Inc. increased its position in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 156.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,300,000 shares of the company's stock after acquiring an additional 3,235,100 shares during the quarter. Bausch Health Companies comprises 1.3% of Maple Rock Capital Partners Inc.'s holdings, making the stock its 13th biggest position. Maple Rock Capital Partners Inc. owned 1.47% of Bausch Health Companies worth $42,718,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Mountain Hill Investment Partners Corp. acquired a new position in shares of Bausch Health Companies during the fourth quarter worth $56,000. Bank of Nova Scotia acquired a new position in Bausch Health Companies during the 4th quarter valued at about $83,000. One68 Global Capital LLC purchased a new stake in Bausch Health Companies in the fourth quarter valued at about $90,000. Alpine Global Management LLC acquired a new stake in Bausch Health Companies in the fourth quarter worth about $114,000. Finally, Tobam grew its stake in shares of Bausch Health Companies by 10.4% during the fourth quarter. Tobam now owns 15,034 shares of the company's stock worth $121,000 after acquiring an additional 1,422 shares during the last quarter. Hedge funds and other institutional investors own 78.65% of the company's stock.
Analyst Ratings Changes
Several equities analysts recently commented on the stock. Royal Bank of Canada increased their price objective on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd. StockNews.com upgraded shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Thursday, May 1st. Finally, Jefferies Financial Group reissued a "hold" rating and issued a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $7.42.
Read Our Latest Research Report on Bausch Health Companies
Bausch Health Companies Stock Performance
Bausch Health Companies stock traded up $0.01 during midday trading on Wednesday, hitting $4.75. 922,307 shares of the company were exchanged, compared to its average volume of 2,662,188. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $9.85. The firm has a market capitalization of $1.76 billion, a PE ratio of -39.54, a price-to-earnings-growth ratio of 0.37 and a beta of 0.34. The business has a fifty day simple moving average of $5.94 and a two-hundred day simple moving average of $7.17.
Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The firm had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. As a group, equities analysts expect that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.
About Bausch Health Companies
(
Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Further Reading
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
